Altura SEC and AdvanceBio SEC HPLC Columns
Altura SEC and AdvanceBio SEC columns are designed and manufactured by Agilent for size exclusion chromatography of biomolecules. The innovative, high-porosity silica particles and unique hydrophilic bonding chemistry provide for exceptional stability with minimal nonspecific interactions.
Altura HPLC columns feature innovative Agilent Ultra Inert technology. This advanced coating blocks active metal sites, ensuring an inert flow path while maintaining the strength, pressure tolerance, and consistency of a traditional stainless‑steel HPLC column. Altura SEC columns are packed with the same SEC media as AdvanceBio SEC columns, with the added benefit of inert column hardware. An Altura SEC column may be substituted for an equal particle and pore size AdvanceBio SEC column for improved peak shape and recovery for metal-sensitive analytes.
SEC columns with 2.7 μm particles are available in four pore sizes: 130 Å for peptides and small therapeutic proteins; 300 Å for monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and other proteins; a new 500 Å pore size for adeno-associated viruses (AAVs) and other large biotherapeutic proteins and oligonucleotides; and a new 1000 Å pore size for virus-like particles (VLPs) and other large biotherapeutics, such as oligonucleotides.
UHPLC SEC columns with sub-2 μm particles are optimized for high resolution, high‑throughput separation, and characterization of size variants. They are offered in two pore sizes: AdvanceBio SEC 1.9 µm, 120 Å is best suited for the analysis of peptides and small therapeutic proteins, while Altura SEC and AdvanceBio SEC 1.9 µm, 200 Å are designed for characterizing mAbs and ADCs.
Altura HPLC columns feature innovative Agilent Ultra Inert technology. This advanced coating blocks active metal sites, ensuring an inert flow path while maintaining the strength, pressure tolerance, and consistency of a traditional stainless‑steel HPLC column. Altura SEC columns are packed with the same SEC media as AdvanceBio SEC columns, with the added benefit of inert column hardware. An Altura SEC column may be substituted for an equal particle and pore size AdvanceBio SEC column for improved peak shape and recovery for metal-sensitive analytes.
SEC columns with 2.7 μm particles are available in four pore sizes: 130 Å for peptides and small therapeutic proteins; 300 Å for monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and other proteins; a new 500 Å pore size for adeno-associated viruses (AAVs) and other large biotherapeutic proteins and oligonucleotides; and a new 1000 Å pore size for virus-like particles (VLPs) and other large biotherapeutics, such as oligonucleotides.
UHPLC SEC columns with sub-2 μm particles are optimized for high resolution, high‑throughput separation, and characterization of size variants. They are offered in two pore sizes: AdvanceBio SEC 1.9 µm, 120 Å is best suited for the analysis of peptides and small therapeutic proteins, while Altura SEC and AdvanceBio SEC 1.9 µm, 200 Å are designed for characterizing mAbs and ADCs.
Product Details
Features
- High-resolution, high-efficiency separation, and accurate quantitation for aggregate and fragment analysis of peptides, proteins, and larger biotherapeutics, such as oligonucleotides, AAVs and VLPs
- Altura Ultra Inert column hardware effectively mitigates analyte-metal interactions, resulting in better peak shape with less tailing and enhanced sensitivity due to improved sample recovery
- Assured consistent SEC column performance to eliminate rework
- Enhanced column lifetime and productivity to meet robust critical quality attribute (CQA) analysis
- Sustainable column packaging uses 50% less material, is made of fully recyclable paper, and reduces shipping carbon footprint by 30%.
How It Works
Applications
Featured References
- Publications
-
- Liu, N. F.; Enomoto, M.; Ikura, M.; et al. Reconstitution and characterization of BRAF in complex with 14-3-3 and KRAS4B on nanodiscs. Protein Science 2024, 33, e5016. DOI: 10.1002/pro.5016.
- Huang, C.-Y.; Lok, Y.-Y.; Lin, C.-H.; et al. Highly reliable GIGA-sized synthetic human therapeutic antibody library construction. Frontiers in Immunology 2023, 14, 1089395. DOI: 10.3389/fimmu.2023.1089395.
- Huang, Y.; Li, Y.; He, R.; et al. Cancer immunogenic cell death via pyroptosis with CXCR4-targeted nanotoxins in hepatocellular carcinoma. Frontiers in Bioengineering and Biotechnology 2024, 12, 1433126. DOI: 10.3389/fbioe.2024.1433126.
- Matsuda, Y.; Leung, M.; Okuzumi, T.; Mendelsohn, B. A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation. Antibodies 2020, 9 (2), 16. DOI: 10.3390/antib9020016.
- Pathak, K.; Perrotti, G.; Rose, S.; Robinett, G.; Kasper, L.; Xia, J.; Escalante, C.; Gomes, F. Characterizing the Content and Structure of AAV Capsids by Size Exclusion Chromatography and Orbitrap-Based Charge Detection-Mass Spectrometry. Journal of the American Society for Mass Spectrometry 2025, 36, 8. DOI: 10.1021/jasms.5c00074.